Lonza’s Pharma Biotech Business Drives Strong H1 2020 Group Sales Growth and Margin Improvement
Lonza today reported strong Group sales growth of 7.7%3 and a resilient CORE EBITDA margin of 29.1%. The results reflect Lonza Group’s robustness to the challenges and uncertainties arising from the COVID-19 pandemic in H1.
July 24, 2020